Evaluating malaria vaccine candidates for pregnant women

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to develop a vaccine to prevent malaria infections during pregnancy, which poses significant risks to both mothers and their unborn children. Researchers will recruit pregnant women aged 15-25 in Mali, who are malaria positive, to participate in in-vitro tests using blood samples. The study will assess the functional activity of antibodies raised against malaria vaccine candidates, comparing them to naturally acquired antibodies. Participants will provide consent for their blood samples to be used in future research and may receive treatment for malaria or anemia if needed.

Why it matters

Who can join: the full rules

* INCLUSION CRITERIA:

A study participant must satisfy the following criteria to be enrolled in this study:

* Pregnant women aged 15-25 years
* Able to provide consent for self
* Malaria positive by rapid diagnostic test (RDT)

EXCLUSION CRITERIA:

* Severe anemia defined as HGB\<7 gr/dL, that may be worsened by 10 mL phlebotomy
* Conditions that in the judgment of the investigator could increase the risk to the volunteer
* Prior enrollment to the study during the same pregnancy

Where it's running

• Ouelessebougou Clinical Research Center
  Bamako, Mali Recruiting

Study contacts

• Principal investigator: Michal Fried, Ph.D. — National Institute of Allergy and Infectious Diseases (NIAID)
• Study coordinator: Michal Fried, Ph.D.
• Email: michal.fried@nih.gov
• Phone: (240) 747-7880

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Lotilaner safety and blood activity in healthy adults in Mali

  This Phase 1b study tests if a single dose of lotilaner is safe, tolerable, and shows mosquito-killing activity in healthy adults living in Mali.

  Recruiting Phase 1 Medicines for Malaria Venture · Bamako · NCT07758985

• See if the R21/Matrix-M malaria vaccine works in real-world settings for kids under 5

  This study tests how well the R21/Matrix-M vaccine protects children under 5 in Burkina Faso and Uganda when used in typical clinical care.

  Recruiting at 12 sites Clinton Health Access Initiative Inc. · Boromo, Boucle Mouhoun and 20 other locations · NCT07749911

• Do malaria vaccines lower the risk of invasive non-typhoidal Salmonella in young children?

  This study will see if the R21/Matrix-M malaria vaccine lowers the chance of invasive non-typhoidal Salmonella disease in children under 5 who come to health facilities with fever in the Kisantu Health Zone (DRC).

  Recruiting International Vaccine Institute · Kinshasa · NCT07416461

• Community spread of multiple infectious diseases in Cambodia from a One Health perspective

  This project will test how common and connected dengue, chikungunya, Zika, Japanese encephalitis, and West Nile infections are among people, animals, and the environment across Cambodia.

  Recruiting Institut Pasteur du Cambodge · Phnom Penh, Phnom Penh · NCT07358910

• Lower-dose and alternate-schedule RTS,S malaria vaccine for young children

  This project will test if smaller doses and different schedules of the RTS,S malaria vaccine are safe and help build immunity in healthy children aged 5 to 60 months who live where malaria is common.

  Recruiting at 2 sites Phase 2 GlaxoSmithKline · Kigali and 1 other locations · NCT07036159

• Optimizing malaria and HIV treatment for children in Busia and Kampala

  We will test whether dolutegravir affects growth and how it interacts with common malaria medicines in children with and without HIV, following them for two years in Busia and Kampala.

  Recruiting at 2 sites Phase 4 Yale University · Kampala and 1 other locations · NCT06967519

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.